SOTAC

Sotac Pharmaceuticals Ltd.

NSE: SOTAC

SME

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

92.00+0.0 (+0.00%)

21 Oct, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

76.5 / 100

Value Score

71.4 / 100

Price Momentum Score

6.0 / 100

QVM Score

49.5 / 100

Key Metrics

Market Cap

101.66

P/E (TTM)

17.63

P/B

1.73

P/S (TTM)

1.00

EV/EBITDA

7.72

CAPE (5Y)

20.54

ROE (TTM)

10.29

ROCE (TTM)

12.22

ROA (TTM)

4.47

Avg 3Y ROE

13.06

Earnings 3Y CAGR

8.66

Sales 3Y CAGR

20.42

Sales 5Y CAGR

15.69

Debt/Equity

0.64

Consensus TP

Strong Buy %

Promoter Holding

72.85

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Sotac Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 17.63 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -42.14%

What is P/E Ratio?

Median: 30.47

Value 17.63

-0.82614.73

Company's earnings are of high quality

Earnings quality score of 82.4 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

82.4 / 100

Negative

Weak price momentum

Price Momentum score of 6.0 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term

What is Price Momentum score?

6.0 / 100

Low dividend yield

The company has a low dividend yield of 0.11%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Sotac Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Sotac Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Sotac Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026	Sep 2026
Total Promoter	72.85	72.85	72.85	72.85	72.85	72.85	72.85
Indian Promoter	72.85	72.85	72.85	72.85	72.85	72.85	72.85
Foreign Promoter	-	-	-	-	-	-	-
Institutions	8.52	8.99	8.88	15.80	16.14	16.79	16.46
Mutual Funds / UTI	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-
FII	8.52	8.99	8.88	15.12	16.14	16.79	16.46
Other Institutions	0.00	0.00	0.00	0.68	0.00	0.00	0.00
Non-Institution	18.64	18.16	18.27	11.35	11.01	10.36	10.69
Bodies Corporate	12.60	11.44	11.60	6.21	5.50	3.49	5.09
Others (incl. Retail) No. of shareholders	6.04 230	6.72 220	6.67 228	5.14 218	5.51 215	6.87 197	5.60 205

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Sotac Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
SAMBHAVNATH INVESTMENTS AND FINANCES PRIVATE LIMITED	13 Mar 2026	sell	₹ 110.55	1.90 lac	₹ 2.10 cr
ADITYA ENTERPRISE	13 Mar 2026	buy	₹ 110.55	1.70 lac	₹ 1.88 cr
GOENKA BUSINESS & FINANCE LIMITED	20 Mar 2025	sell	₹ 120.00	1.84 lac	₹ 2.20 cr
CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND	20 Mar 2025	buy	₹ 120.00	1.84 lac	₹ 2.20 cr
SAMBHAVNATH INVESTMENTS AND FINANCES PRIVATE LIMITED	04 Mar 2025	sell	₹ 102.80	1.54 lac	₹ 1.58 cr
CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND	04 Mar 2025	buy	₹ 102.80	1.54 lac	₹ 1.58 cr
SANDHYA SINGH GAHLAUT	02 Jan 2025	sell	₹ 116.30	99.60 k	₹ 1.16 cr
NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND	22 Feb 2024	buy	₹ 135.42	72.00 k	₹ 97.50 lac
SUNFLOWER BROKING PRIVATE LIMITED	21 Feb 2024	sell	₹ 132.18	70.80 k	₹ 93.58 lac
NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND	21 Feb 2024	buy	₹ 132.16	73.20 k	₹ 96.74 lac

Corporate Actions

History of Sotac Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 0.20/share
Record date: 23rd Sep 2026Ex-date: 23rd Sep 2026
Announced on: 26th May 2026
Dividend₹ 0.10/share
Record date: 19th Sep 2025Ex-date: 19th Sep 2025
Announced on: 28th May 2025

Company Profile

Overview of Sotac Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Sotac Pharmaceuticals Ltd is an India-based pharmaceutical company. The Company manufactures pharmaceutical products such as tablets, capsules (general & beta-lactum), oral liquid, dry syrup and external preparations. Its services include contract manufacturing, loan license, formulation and develop...

Key personnel

Mr. Brijeshkumar Ranchhodbhai Patel

Chief Financial Officer

Mr. Pankaj Prabhakar Mahabaleshwarkar

Chief Operating Officer

Ms. Niyati Dipesh Parikh

Compliance Officer, Company Secretary

Mr. Sharadkumar Dashrathbhai PatelD

Executive Chairman of the Board, Managing Director

Mr. Dineshkumar Babulal GelotD

Whole Time Director

Mr. Chetankumar Bachubhai PatelD

Executive Director

Mr. Vishalkumar Devrajbhai PatelD

Executive Director

Mr. Bhavinkumar Prafulbhai JoshiD

Non-Executive Independent Director

View all

Incorporated on

18 Dec 2015

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

13 Apr 2023

Free Float

Website

https://sotacpharma.com/

Phone no.

+919081993300

Address

PF-21 & PF-22/A, Charal, Industrial Estate, GIDC-II, Sanand, AHMEDABAD, 382110, India

Frequently Asked Questions

What is the current share price of Sotac Pharmaceuticals Ltd.?

The current share price of Sotac Pharmaceuticals Ltd. is ₹ 92.00 as of 21 Oct 2026.

What is the market capitalisation of Sotac Pharmaceuticals Ltd.?

The market capitalisation of Sotac Pharmaceuticals Ltd. stands at ₹ 101.66 Cr.

What is the PE ratio of Sotac Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Sotac Pharmaceuticals Ltd. is 17.63 as of the latest trailing twelve months data.

What is the ROE and ROCE of Sotac Pharmaceuticals Ltd.?

Sotac Pharmaceuticals Ltd. has a Return on Equity (ROE) of 10.29% and a Return on Capital Employed (ROCE) of 12.22% as per the latest financial reports.

What is the 52-week high and low of Sotac Pharmaceuticals Ltd.?

The 52-week high of Sotac Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Sotac Pharmaceuticals Ltd.?

The dividend yield of Sotac Pharmaceuticals Ltd. is 0.11% based on the current market price.

What is the FII and DII holding in Sotac Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 16.46%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 5.60% of Sotac Pharmaceuticals Ltd. shares.

What sector does Sotac Pharmaceuticals Ltd. belong to?

Sotac Pharmaceuticals Ltd. operates in the Healthcare sector.

What is the beta of Sotac Pharmaceuticals Ltd.?

The beta of Sotac Pharmaceuticals Ltd. is 0.25, indicating its price volatility relative to the broader market.

What is the RSI of Sotac Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Sotac Pharmaceuticals Ltd. is 35.40, placing it approaching oversold territory. An RSI above 70 is considered overbought and below 30 is considered oversold.